Skip to main content
  • Saved

made a Post

Dapagliflozin and Empagliflozin in Heart Failure | IJGM

Dapagliflozin and Empagliflozin in Heart Failure | IJGM

Source :

https://www.dovepress.com/dapagliflozin-and-empagliflozin-in-heart-failure-with-reduced-ejection-peer-reviewed-fulltext-article-IJGM

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including dapagliflozin and empagliflozin, are a new type of oral glucose-lowering drugs that can control blood glucose by inhibiting SGLT2 in the kidney. The DAPA-HF trial and the EMPEROR-Reduced trial suggested that dapagliflozin and empagliflozin, respectively, could lower the incidences of cardiovascular adverse events in patients suffering from heart failure with reduced ejection fraction (HFrEF).



Conclusion: Despite its many limitations, this study suggested that different SGLT2 inhibitors might have differences regarding efficacy in HFrEF. We look forward to future studies to verify our conjectures.